Kim N. Chi, MD

Kim N. Chi, MD, FRCPC, discusses the significance of the phase 3 MAGNITUDE trial, including its evaluation on patient-reported outcomes, in patients with BRCA1/2-altered metastatic castration-resistant prostate cancer.

Kim N. Chi, MD, FRCPC, discusses results from the MAGNITUDE trial, including those on survival and patient-reported outcomes in patients with BRCA-positive metastatic castration-resistant prostate cancer receiving niraparib plus abiraterone acetate and prednisone.

Kim N. Chi, MD, discusses the safety findings for the next-generation androgen receptor inhibitor apalutamide in combination with androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer, according to findings from the phase III TITAN study. This combination was compared with placebo and ADT and presented at the 2019 ASCO Annual Meeting.

Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.